NEW YORK, Dec 10 (Reuters) - Online telehealth company Hims and Hers Health is launching its weight-loss membership and ...
Hims & Hers Health ($HIMS) is strengthening its position in the UK with the launch of weight-loss programs. This launch will ...
The U.S. Food and Drug Administration’s recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question. Check out the current price ...
Online telehealth company Hims and Hers Health HIMS.N is launching its weight-loss membership and treatment plans in the UK ...
The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...
In a strategic pivot, the company has launched its weight-loss program in the United Kingdom. There, Hims & Hers is offering legitimate, branded medications—Novo Nordisk's Wegovy and Eli Lilly's ...
Investing.com -- Hims Hers Health Inc (NYSE:HIMS) stock fell 4.4% Wednesday after U.S. lawmakers introduced legislation that could significantly impact the company’s fastest-growing product category.
Asianet Newsable on MSN
Retail Traders Crown Novo Nordisk As Long-Term Weight Loss King — Even As Eli Lilly Hits $1T And Viking Fans Tout ‘M&A Prize’
Users pointed to emerging drug pipelines, GLP-1 expansion and rising M&A pressure across the sector.
Since my last update, Hims & Hers Health, Inc. stock has fallen by >25% before recovering all of its losses. Recent news flow has been mixed, with some insider selling and criticism of some business ...
One of largest U.S. telehealth providers expects to ride wave of exploding demand for weight-loss drug semaglutide when it ...
Hims & Hers Health stock has seen its fair value estimate trimmed from about $46.00 to roughly $44.36 per share, even as analysts grow more optimistic about its long term revenue trajectory. Stronger ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback